Diabetic Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X Receptor Activation in a Type 1 Diabetes Model
暂无分享,去创建一个
L. Adorini | F. Gonzalez | J. Kopp | J. Verlander | T. Jiang | Xiaoxin X. Wang | M. Levi | M. Pruzanski | Cydney Urbanek | Yupanqui A Caldas | P. Scherzer | Shinobu Miyazaki‐Anzai | Yan Shen | H. Santamaria | N. Solis | Linda B. Lewis
[1] X. Prieur,et al. Lipotoxicity in macrophages: evidence from diseases associated with the metabolic syndrome. , 2010, Biochimica et biophysica acta.
[2] Z. Varghese,et al. An update on the lipid nephrotoxicity hypothesis , 2009, Nature Reviews Nephrology.
[3] L. Adorini,et al. The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria. , 2009, American journal of physiology. Renal physiology.
[4] C. Alpers,et al. Mouse models of diabetic nephropathy. , 2005, Journal of the American Society of Nephrology : JASN.
[5] B. Banas,et al. The mesangial cell revisited: no cell is an island. , 2009, Journal of the American Society of Nephrology : JASN.
[6] B. M. Forman,et al. Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response , 2008, Hepatology.
[7] Jeffrey E. Thatcher,et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis , 2008, Proceedings of the National Academy of Sciences.
[8] Johan Auwerx,et al. Targeting bile-acid signalling for metabolic diseases , 2008, Nature Reviews Drug Discovery.
[9] S. Shankland,et al. Proteinuria in diabetic kidney disease: a mechanistic viewpoint. , 2008, Kidney international.
[10] B. Chang,et al. Deficiency of Adipose Differentiation-Related Protein Impairs Foam Cell Formation and Protects Against Atherosclerosis , 2008, Circulation research.
[11] M. Kretzler,et al. From Fibrosis to Sclerosis , 2008, Diabetes.
[12] Pengfei Wu,et al. LOX-1 and inflammation: a new mechanism for renal injury in obesity and diabetes. , 2008, American journal of physiology. Renal physiology.
[13] K. Suszták,et al. The Notch pathway in podocytes plays a role in the development of glomerular disease , 2008, Nature Medicine.
[14] X. Deng,et al. SREBPs: the crossroads of physiological and pathological lipid homeostasis , 2008, Trends in Endocrinology & Metabolism.
[15] H. Sone,et al. Involvement of glomerular SREBP-1c in diabetic nephropathy. , 2007, Biochemical and biophysical research communications.
[16] T. Warner,et al. Farnesoid X Receptor Ligands Inhibit Vascular Smooth Muscle Cell Inflammation and Migration , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[17] C. Huard,et al. Abstract 832: The Farnesoid X Receptor (FXR) Antagonizes Oxidized LDL Receptor, LOX-1, Activation , 2007 .
[18] T. Jiang,et al. Farnesoid X Receptor Modulates Renal Lipid Metabolism, Fibrosis, and Diabetic Nephropathy , 2007, Diabetes.
[19] Y. Terauchi,et al. Role of altered renal lipid metabolism in the development of renal injury induced by a high-fat diet. , 2007, Journal of the American Society of Nephrology : JASN.
[20] E. Bottinger. TGF-β in renal injury and disease , 2007 .
[21] John J Rossi,et al. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-β-induced collagen expression via inhibition of E-box repressors , 2007, Proceedings of the National Academy of Sciences.
[22] B. Croker,et al. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. , 2007, Journal of the American Society of Nephrology : JASN.
[23] F. Strutz,et al. Renal fibroblasts and myofibroblasts in chronic kidney disease. , 2006, Journal of the American Society of Nephrology : JASN.
[24] R. Harris,et al. Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. , 2006, Journal of the American Society of Nephrology : JASN.
[25] T. Jiang,et al. Regulation of Renal Fatty Acid and Cholesterol Metabolism, Inflammation, and Fibrosis in Akita and OVE26 Mice With Type 1 Diabetes , 2006, Diabetes.
[26] R. Evans,et al. Anatomical Profiling of Nuclear Receptor Expression Reveals a Hierarchical Transcriptional Network , 2006, Cell.
[27] Timothy M Willson,et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[28] T. Jiang,et al. Diet-induced Obesity in C57BL/6J Mice Causes Increased Renal Lipid Accumulation and Glomerulosclerosis via a Sterol Regulatory Element-binding Protein-1c-dependent Pathway* , 2005, Journal of Biological Chemistry.
[29] Jianping Jin,et al. Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. , 2005, Diabetes.
[30] J. McManaman,et al. Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes. , 2005, Diabetes.
[31] Michael Brownlee,et al. The pathobiology of diabetic complications: a unifying mechanism. , 2005, Diabetes.
[32] R. Atkins,et al. Macrophages in streptozotocin-induced diabetic nephropathy: potential role in renal fibrosis. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[33] Sander M Houten,et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. , 2004, The Journal of clinical investigation.
[34] S. Quaggin,et al. A podocentric view of nephrology , 2004, Current opinion in nephrology and hypertension.
[35] C. Abrass. Cellular Lipid Metabolism and the Role of Lipids in Progressive Renal Disease , 2004, American Journal of Nephrology.
[36] P. Edwards,et al. Peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α) regulates triglyceride metabolism by activation of the nuclear receptor FXR , 2004 .
[37] Masataka Harada,et al. A G Protein-coupled Receptor Responsive to Bile Acids* , 2003, The Journal of Biological Chemistry.
[38] Grace Guo,et al. The Farnesoid X-receptor Is an Essential Regulator of Cholesterol Homeostasis* , 2003, The Journal of Biological Chemistry.
[39] Takao Nakamura,et al. Identification of membrane-type receptor for bile acids (M-BAR). , 2002, Biochemical and biophysical research communications.
[40] T. Willson,et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. , 2002, Journal of medicinal chemistry.
[41] Lijun Sun,et al. Role of Sterol Regulatory Element-binding Protein 1 in Regulation of Renal Lipid Metabolism and Glomerulosclerosis in Diabetes Mellitus* , 2002, The Journal of Biological Chemistry.
[42] Masahiro Tohkin,et al. Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis , 2000, Cell.
[43] D. Heudes,et al. Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. , 2000, Diabetes.
[44] T. Hirano. Lipoprotein abnormalities in diabetic nephropathy. , 1999, Kidney international. Supplement.
[45] W. Kriz,et al. Synaptopodin: An Actin-associated Protein in Telencephalic Dendrites and Renal Podocytes , 1997, The Journal of cell biology.
[46] A. Krolewski,et al. Hypercholesterolemia--a determinant of renal function loss and deaths in IDDM patients with nephropathy. , 1994, Kidney international. Supplement.
[47] Ross Ward,et al. United States Renal Data System , 2011 .
[48] F. He,et al. FXR-mediated regulation of eNOS expression in vascular endothelial cells. , 2008, Cardiovascular research.
[49] K. Ley,et al. Leukocyte recruitment and vascular injury in diabetic nephropathy. , 2006, Journal of the American Society of Nephrology : JASN.
[50] R. Atkins,et al. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. , 2004, Kidney international.